
- Remove this product from my favorite's list.
- Add this product to my list of favorites.
Products
Newsletter
![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Background
Early activation antigen CD69 is also known as C-type lectin domain family 2 member C (CLEC2C), Activation inducer molecule (AIM), Early T-cell activation antigen p60, Leukocyte surface antigen Leu-23. CD69 contains one C-type lectin domain. CD69 / CLEC2C is expressed on the surface of activated T-cells, B-cells, natural killer cells, neutrophils, eosinophils, epidermal Langerhans cells and platelets. CD69 is induced by antigens, mitogens or activators of PKC on the surface of T and B-lymphocytes and by interaction of IL-2 with the p75 IL-2R on the surface of NK cells. CD69 / CLEC2C involved in lymphocyte proliferation and functions as a signal transmitting receptor in lymphocytes, natural killer (NK) cells, and platelets.
Source
Recombinant Human CD69 /CLEC2C Protein (rhCD69), His Tag (CD9-H5222) is expressed from human 293 cells (HEK293). It contains AA Ser 62 - Lys 199 (Accession # AAH07037).
Predicted N-terminus: Ser 62
Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 16.8 kDa. The protein migrates as 20-26 kDa under reducing (R) condition (SDS-PAGE) due to different glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
(1) "Auger emitter in combination with Olaparib suppresses tumor growth via promoting antitumor immune responses in pancreatic cancer"
Zhong, Zhang, Wang et al
Invest New Drugs (2024)
(2)"Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients"
Dalle, Verronese, N'Kodia et al
Oncoimmunology (2024) 13 (1), 2372118
(3) "Keratinocytes stimulate MAIT cells to produce granzyme B via MR1 and cytokines in oral lichen planus"
Jiang, Wang, Zhou
Oral Dis (2024)
Showing 1-3 of 6522 papers.
Follow us